IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
+0.21 (+0.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close107.59
Bid107.14 x 1000
Ask108.16 x 1200
Day's Range107.25 - 108.13
52 Week Range94.20 - 119.30
Avg. Volume2,678,658
Net Assets8.53B
PE Ratio (TTM)3.75
YTD Return-2.92%
Beta (3y)1.44
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist2 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • InvestorPlace3 days ago

    Investors Need to Adopt a Different Mindset for Big Pharma and Biotech Stocks

    The ability to sell new drugs hinges on approvals from government bodies such as the Food and Drug Administration (FDA). As a result, biotech companies, and to some degree, large drug companies, go into business ventures without the certainty of ever earning revenues, let alone profits. Biotech stocks often become some of the most difficult to evaluate.

  • InvestorPlace4 days ago

    Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It

    Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock has been decimated over the years. This morning the stock is rallying on the news that the famed investor Warren Buffett doubled his stake in Teva stock. Wall Street loves to chase Buffett’s investments.

  • 5 Top Stock Trades for Monday Morning
    InvestorPlace6 days ago

    5 Top Stock Trades for Monday Morning

    On Friday, stocks digested the big rally over the past week, with many names trading in a rather tight range. That’s something we haven’t seen in a while, with markets more volatile in 2018 vs 2017. In any regard, here are the top stock trades we’re watching for this week.Top Stock Trades for Monday #1: Nvidia (NVDA)

  • Investopedia16 days ago

    Biotech Stocks Set to Breakout

    Biotech shares may be nearing a breakout, based on technical analysis, using the iShares  Nasdaq Biotech ETF ( IBB ) as a proxy. The ETF has stubbornly stayed above $100 after multiple attempts for sellers break to the critical support level. Stocks like Celgene Corp. ( CELG ), Biogen Inc. ( BIIB) and Amgen Inc. ( AMGN) are among the most significant names in the sector.

  • Investopedia25 days ago

    3 Charts That Suggest Biotech Stocks Are Headed Lower

    Rising levels of market volatility and subsequent selling pressure have started to take hold of the strongest performing market segments such as biotechnology. The sudden shift in sentiment now has some active traders talking about a long-term shift in trend. Traders who want to gain exposure to a broad range of biotechnology companies often look to exchange-traded products such as the iShares Nasdaq Biotechnology ETF.

  • Investopedia25 days ago

    Why Biogen's Stock Rebound Is Good News for Biotechs

    An analysis of the technical chart of Biogen Inc. ( BIIB) shows the stock could be set to rebound by about 7%, giving shares the chance to rise back towards $282 from its price of roughly $263, a jump of about 7.5%. Biogen shares were up by roughly 1% on April 24, after the company reported better than expected first-quarter earnings per share, and revenue that was in line with estimates. Biogen's stock has been hit hard in 2018, with the stock down by nearly 30%, since late January peaking near $370 per share. Biogen shares fell to an intraday low of $251, a significant technical support level, that goes back to July of 2016.

  • Market Realistlast month

    No Bid Coming for Shire Reportedly

    CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier.

  • ETF Databaselast month

    Trending: Investors Apathetic to Barclays' $1.2 Billion ETN Shutoff

    This week, investors were preoccupied with Russia, as the country’s equities fell dramatically after the relations with countries in the West, including the U.S., deteriorated. First in the list, however, is Barclays Capital, as the asset management arm of the British bank said it would shut down a host of exchange-traded notes (ETNs). Russia is second in the list followed by crude oil, which has been on a tear lately thanks to dropping stockpiles in the U.S. Leveraged ETFs and biotechnology stocks close the list. Check our previous trends edition at Trending: Soybean Prices Whipsaw on Trade War Fears.

  • Why These Small Cap Biotech ETFs are Soaring
    Zackslast month

    Why These Small Cap Biotech ETFs are Soaring

    These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

  • Investopedialast month

    3 Biotech Stocks Analysts Have Been Too Bullish On

    Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.

  • InvestorPlacelast month

    Exact Sciences Corporation Could Break Out Despite Steep Drop in Biotech

    EXAS stock is down almost 29% in the same period. Exact is a promising laboratory and research firm in the business of screening patients for colon cancer. Patient compliance for the screening test is at a modest 65% .

  • Investopedialast month

    Biotech's Exact Sciences Seen Plunging 25%

    With shares around $38.75, options traders are betting the stock falls by another 25% by Dec. 31.

  • Market Realistlast month

    Can You Avoid the Tariff Trouble in the S&P 500?

    The market did kind of decide to shrug off tariffs and hope they were more of a bargaining chip. If we shrug off the tariffs today, that would be a big win for the market. When they move up, the market worries about choking off growth.

  • Barrons.com2 months ago

    Biotech Sector Could See New Life

    Biotech hasn't had a great start to the year: The iShares Nasdaq Biotechnology ETF (IBB) is down 4.4% year-to-date, and while the SPDR S&P Biotech ETF (XBI) has been the better performer of the two, as Barron's predicted, it's fallen 1.4%.  However, Oppenheimer's Leah Rush Cann thinks that the group could be poised for a positive reversal, based on valuation--which she believes looks attractive--along with earnings growth expectations. Cann writes that she has long held that the biggest catalyst for biotech stocks is the increase expectations for earnings for 2019, and now that that's finally happened, she's more optimistic about the stocks. The Street now expects biotech's earnings growth will exceed the S&P 500's by 20 basis points, a reversal from the pat two years, when biotechs were expected to lag the index.

  • MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus
    Yahoo Finance Video4 days ago

    MARKETS: Russell 2000 hits all-time high; Walmart earnings on deck; oil prices reverse; healthcare stocks in focus

    Yahoo Finance's Seana Smith on midday market action.

  • Trump lets drug companies off the hook
    Yahoo Finance Video9 days ago

    Trump lets drug companies off the hook

    Trump's plan to lower drug prices does not call for the one move many experts believe would be most effective: A new law that would allow Medicare to negotiate with pharmaceutical providers.

  • Yahoo Finance Live: The Final Round - May 11th, 2018
    Yahoo Finance Video9 days ago

    Yahoo Finance Live: The Final Round - May 11th, 2018

    Yahoo Finance's LIVE stock market coverage and analysis.

  • Pfizer falls to session low
    CNBC Videos19 days ago

    Pfizer falls to session low

    CNBC's Meg Tirrell reports on Pfizer stock lower during the company earnings conference call and comments from the Pfizer CEO.

  • What strong global growth means for US markets
    CNBC Videoslast month

    What strong global growth means for US markets

    Kevin Mahn, Hennion and Walsh Asset Management, and Sorin Roibu, Brandywine Global, discuss the IMF's 3 percent growth forecast and what to expect this earnings season.

  • Earnings bar too high? Experts weigh in
    CNBC Videoslast month

    Earnings bar too high? Experts weigh in

    Chris Zaccarelli, Independent Advisor Alliance, and Dan Wantrobski, Janney Montgomery Scott, discuss whether the market's response to bank earnings is indicative of things to come.

  • Yahoo Finance Contributors9 days ago

    Stock Market Analysis 5/11/18

  • Stock Market Analysis 4/18/18
    Yahoo Finance Contributorslast month

    Stock Market Analysis 4/18/18

  • Yahoo Finance Contributorslast month

    Stock Market Video Analysis 4/14/19

  • Stock Market, Gold & Bitcoin Analysis 4/6/18
    Yahoo Finance Contributorslast month

    Stock Market, Gold & Bitcoin Analysis 4/6/18